Opinion
Pfizer’s Comirnaty mRNA COVID Vaccine Manufacturing Has Dropped by 89% Due to Decrease in Demand
The Follow the Money Team’s new report on Pfizer’s financials, based on Pfizer’s Q1 2023 reporting, offers many important insights:
- Pfizer reports that its mRNA COVID vaccine, Comirnaty®, manufacturing activities, performed on behalf of BioNTech, dropped 89% to only $5 million quarter-over-quarter.
- In its Q1 2023 report, Pfizer assumes no growth in market share for COVID-19 vaccinations.
- Pfizer notes the Comirnaty’s decrease in uptake is due to “fewer primary vaccinations and non-compliance.”
- Pfizer’s Q1 2023 revenue was down 28.7%, and Earnings Per Share dropped 29% from Q1 2022.
- Pfizer’s 2023 revenue guidance is about $30 billion lower than 2022.
- The company’s stock price has dropped from a high of $59.48 on December 17, 2021, to a 52-week low of $36.51 on May 17, 2023, a 37% fall in just over 12 months.
Please read the full report below.
FTM Pfizer Financial Performance Micro Report #4
https://dailyclout.io/wp-content/uploads/FTM-Pfizer-Financial-Performance-Micro-Report-4-3.pdf
This DailyClout article is the writer’s opinion.
One of our country’s most important freedoms is that of free speech.
Agree with this essay? Disagree? Join the debate by writing to DailyClout HERE.
One of our country’s most important freedoms is that of free speech.
Agree with this essay? Disagree? Join the debate by writing to DailyClout HERE.
Myocarditis, brought to you by Pfizer!
Their goal is the death of as many people as possible.
True! for years I’ve been telling my friends in the West that Cuba, Venezuela, Afghanistan, Iraq, Libya and Syria were never your enemies, it was always your own government, your CIA, your FBIA, your Monetary System. Glad people in USA and UK are waking up now!
“noncompliance?”
I thought this was totally voluntary according to Biden?